Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares MBS ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.78 (market cap $29.60B), while iShares MBS ETF trades at $93.23. Which is the better fit depends on your goals.
| ALNY | MBB | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | — |
52-Week High | $491.22 | $96.91 |
52-Week Low | $205.48 | $92.72 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
MBB trades at $93.28, up 0.38% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent corporate actions include dividend payments of $0.33-$0.34 per share in mid-2026. Focus Financial Network increased its stake by 13.8% in the latest quarter, holding 49,056 shares as of its most recent SEC filing.
The outlook remains cautious due to bearish technical indicators and limited fundamental data availability. Key risks include market volatility and reliance on institutional interest. Investment opportunities hinge on dividend income and potential institutional accumulation, but the lack of current financial metrics warrants careful evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
